Administration of the low molecular weight heparin (LMWH) enoxaparin sodium [‘Lovenox’; Rhône-Poulenc Rorer] in place of unfractionated heparin is proving to be of great value as post-thrombolytic therapy in patients with acute myocardial infarction (MI). This option is a well tolerated, efficacious, cost-effective, and more convenient alternative to unfractionated heparin, according to the results of study presented at the 70th Scientific Sessions of the American Heart Association [Orlando, US; November 1997]. In the study, enoxaparin sodium significantly reduced the risk of cardiac events compared to standard unfractionated heparin in patients with acute MI, reported Dr Charles Wilson, from Antrim Hospital, Northern Ireland.